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Summary 
The anti-idiotypic (anti-Id) antibody (Ab) 9G4 binds a cross-reactive idiotope (CRI) present 
in  a  select  group  of human autoantibodies.  This  Id  has  been  localized  to  the  portion  of 
immunoglobulin (Ig) heavy (H) chains encoded by the V,4-21 gene segment, a member of the 
human V.4 family. This gene segment is utilized by essentially  all cold agglutinin (CA) Abs 
with  I/i  specificity  isolated  from  patients  with  CA  disease  stemming  from  chronic 
lymphoproliferative  disorders. In this study, mutational analysis of a CA has been used to determine 
the structural basis for 9G4 binding to Abs utilizing the VH4--21 gene segment. Recombinant 
CA H chain mutants were produced and their 9G4 reactivity determined. Mutants were generated 
by exchanging V.4-21 sequences in the FK1, CDR1, and CDK2 with corresponding sequences 
from a closely related gene segment V71-2, a V.4 family member that is associated neither with 
Abs having CA activity nor with Abs that react with 9G4.  The results indicate that the motif 
AVY at amino acid positions 23-25 in FR1 defines the 9G4 idiotope. Reaction of these recombinant 
Abs with a polyclonal rabbit anti-CA antiserum absorbed to render it specific for a CA CRI 
also maps predominantly to FR1. These findings indicate that the solvent-exposed FR1 plays 
an important role in eliciting an immune response to Igs. 
1  r'~he phenomenon of cross-reactive idiotypes (CRI)  was 
.I.  first described in 1968 by Williams et al. (1) who demon- 
strated that many human cold agglutinins (CA) reacted with 
absorbed polyclonal antisera  raised in rabbits against three 
purified human CA. The antisera did not react with other 
macroglobulins lacking the ability to agglutinate RBC at low 
temperature. This result suggested the presence of V region 
antigenic structures shared by CA and was the first demon- 
stration of shared Id among nonidentical Abs derived from 
unrelated individuals (2). 
The rat mAb 9G4 has a reactivity profile that corresponds 
to the absorbed polyclonal sera mentioned above. In partic- 
ular,  essentially  all CA from patients with cold agglutinin 
disease (CAD) having I/i specificity show reactivity with 9G4 
(3). More recently it has been shown that CA that are specific 
1 Abbreviations  used  in  this  paper'.  CA,  cold  agglutinin;  CAD,  cold 
agglutinin disease; CRI, cross-reactive  idiotope; SOE, splicing by overlap 
extension. 
for the I/i antigens, and produced under chronic lympho- 
proliferative conditions, almost uniformly utilize the VH4-21 
gene segment (4-8).  The VH4-21 gene segment is also uti- 
lized by some Abs having reactivity against structurally dis- 
tinct blood group antigens (9), as well as Abs with anti-DNA 
(10) and KF (5,  11) activities.  With the exception of FOG 
1, an Ab with anti-KBC D  antigen specificity, all of the 
V.4-21-derived Abs tested were 9G4 reactive,  whereas Ig 
using gene segments from the other V. families  did not 
react with 9G4 (4, 5, 12, 13). 9G4, therefore, specifically  reacts 
with Abs that are V,4-21 gene segment encoded, a group 
of Ig which encompasses a variety of antigenic specificities. 
Hence, the 9G4 Id, like the CRI which reacts with the ab- 
sorbed polyclonal anti-CA antisera,  is a marker for a select 
group of Abs. 
CRI were serologically defined as determinants associated 
with the V region of Ab molecules having the same or similar 
antigen-binding specificity and/or were expressed from related 
Ig genes (1, 2). They are determinants that can be formed 
from structures restricted either to the H  or the L chain or 
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ment usage indicates that the 9G4 reactive idiotope is restricted 
to the H chain alone. The L chains associated with CA pre- 
dominantly use the VKIII family, especially anti-I CA, how- 
ever, K chains from the VgI and VglI families  (4, 5, 8,  15) 
and )x chains have also been described, especially in associa- 
tion with anti-i CA (1, 5, 8, 16-18). Abs against various blood 
group antigens that react with 9G4, are also associated with 
both K  and k chains (12). Sequence analysis of  a series of  eleven 
CA H and L chains indicates that there is no homology among 
these Abs  in the H  chain CDK3  and,  whereas  there is  a 
preponderant usage of J,4, other J, segments are also used 
(4,  5,  8).  Abs of both the IgM and IgG isotypes are also 
9G4 reactive indicating that the C  region is not a factor in 
forming the determinant (19). Thus, since there was nothing 
obviously similar in the D  or Ja segments, the CH region nor 
in the L chains,  it was concluded that the V.4-21 gene seg- 
ment is responsible for the 9G4 CRI. 
The structural basis of the CKI in V.4-21 recognized by 
9G4 has not been determined. In the present study, muta- 
tional analysis and expression of recombinant Abs has allowed 
us to identify and locate the amino acids involved in the idio- 
tope recognized by 9G4.  We chose to express and mutate 
the CA FS-7, which utilizes the V,4-21  gene segment in 
germline configuration, as the focus of this study. A  series 
of site-directed mutations indicates that the 9G4 reactive CRI 
is localized to amino acids 23-25 in FR1. In addition, a poly- 
clonal rabbit anti-CA antiserum, absorbed to render it specific 
for a CA CKI, recognized a determinant on the recombinant 
Abs which also  maps to FK1. 
Materials  and Methods 
Viruses and Cells.  Autographa californica nuclear polyhedrosis  virus 
(AcMNPV) and recombinant viral stocks were produced and as- 
sayed in the SIJodol~terafrugiperda cell line Sf9. Sf9 cells were grown 
in TNM-FH medium supplemented with 10% FCS plus penicillin 
(100 U/m1), streptomycin  (100/~g/ml), and fungizone (0.25/~g/ml). 
Recombinant Abs were produced in Sf9 cells adapted to growth 
in serum-free medium (Sf-900; GIBCO BRL, Gaithersburg, MD). 
All procedures were essentially as previously described (20-22). 
PCR  Conditions.  Oligonucleotides  were designed for PCR- 
SOEing (splicing by overlap extension; 23) such that the overlap 
region between the primers and the portions of the primers that 
pair with the template had a melting temperature of 60-64~  All 
of the complementary bases were added to one of the two internal 
primers.  The external  primers  used  for all  IgM  Abs  were  5' 
GGAATTCGCCATGGAACACCT  3'  at  the  5'  end  and  5' 
TGCATGCATTCTAGAGCCTGTGGGCAG  3' at the 3' end. The 
total reaction volume was 100/A,  which was overlaid with 100 
/A of mineral oil. Taq polymerase was used at 1 U per reaction. 
The PCIL conditions involved two cycles  of 1 min at 94~  2 min 
at 52~  and 3 min at 72~  followed by 23 cycles of I  min at 
94~  2 rain at 59~  and 3 min at 72~  ending with 10 min 
at 72~ 
Gene Construction.  Ab genes for both H and L chains of Ab 
FS-7 were cloned from FS-7, an immortalized human B cell line 
from a patient with CAD (8). Total RNA was isolated and used 
as template for cDNA synthesis. V regions were amplified  by PCR 
and cloned into the Bluescript vector (Stratagene, La Jolla, CA) 
using  standard procedures (8). As  the V~ sequence was cloned 
minus its signal sequence, a K signal sequence was attached and 
the C~ region was spliced to this product. The V. region had been 
cloned with its signal sequence. The C~ region was then fused to 
the V. region. The source of the K  signal and C~ region sequences 
were from a RF r  clone (11). The C~ region was amplified from 
a clone of the antithyroglobulin H chain isolated from Ab25 (24). 
The CDR1-FR3 V71-2 sequence was PCR amplified from clone 
V.4-21  (24a) and  spliced to  the  FR1  sequence of V71-2 and 
CDR3-C# sequence in two separate SOEing reactions to generate 
the entire V71-2 sequence. Primer sequences for the leader-FR1 
were 5' GGAATTCGCCATGGAACACCT  3' and 5' GTAGTAAC- 
TACCACTGCTGACGGAGCCACCAGAGACCGT  3';  for the 
V71-2 CDR1-FK3 they were 5' GTCAGCAGTGGTAGT'EACTAC 
3' and 5' CAGCCACTGCTCTCTGCCTCTCGCACAGTAATA- 
CACAGC 3' and for the CDR3-C/~ they were 5' GGCAGAGAG- 
CAGTGGCTG 3' and 5' TGCATGCATTCTAGAGCCTGTGGG- 
CAG 3: All PCR amplified fragments were run on a 1% agarose 
gel to separate the PCR fragment from the oligonudeotide primers 
before SOEing. The DNA fragments were excised from gels as 
agarose plugs and melted at 75~  for 2 min. 5-/A aliquots of  both 
DNA bands were combined in a SOEing reaction in the presence 
of the external oligomers. 
Oligonucleotide-directed Mutagenesis.  All mutations were carried 
out by PCR-SOEing using mutagenic oligonucleotides (25). Tem- 
plates included double-stranded DNA isolated from mini-plasmid 
preparations  and  single-stranded DNA.  The oligomer  used to 
generate  the N-FW1  mutant  was:  5'  AAGGCTTCACCAGT- 
CCTGGGCCC__GACTCCTGCAGCTG 3';  for  C-FW1/CDR1 
it  was  5'  GTAGTAACTACCAC~TGACGGAGCCACCA- 
GAGACAGTGCAGGTGAG 5'; for CDR2 it was 5' TGTAGT- 
TGG'IGCTCCCACTGTAATAGATATACCCAATCCACTC  3'; 
for FK1 (71-2) it was 5' GCTCCAGTAGTAACCACTGAAGGAG- 
CCACCAGAGACAGTGCAGGT 3'; for C-FW1 it was 5' GCT- 
CCAGTAGTAACCACTGAAGGAGCCACCAGGAGCCAC- 
CAGAGACAGTGCA 3'; for CDR1 it was 5' GTAGTAACTAC- 
CACTGCTGACGGACCCACCATAGACAGC 3'; and for 25Y~ 
25F it was 5' GTAACCACTGAAGGACCCACCAAAGACAG  3'. 
The underlined bases indicate mutated  sites. 
Transfer  Vector.  The  transfer  vector  for  all  constructs  was 
pH360NX. It is essentially as described (26) except for the addi- 
tion of an XbaI site. An NcoI site was created at the translation 
initiation site for polyhedrin synthesis and an XbaI site was gener- 
ated to provide for directional cloning of foreign genes. Human 
Ig genes were amplified  by PCR using oligomers containing NcoI 
and XbaI restriction enzyme sites. After PCR-SOEing,  the genes 
were phenol/chloroform  extracted, ethanol precipitated, digested 
with NcoI and XbaI, and purified by electrophoresis  through 0.8% 
low melting temperature agarose gels. The DNA bands were ex- 
cised as gel plugs, and ~20/A of melted plug were added to liga- 
tion reactions containing the NocI-XbaI-digested  and -dephos- 
phorylated transfer vector. Ligation products were transformed into 
Escherichia coli BSJ72 (TG1, k r, Snr; a gift from Dr. Steve Henikoff, 
Cold Spring Harbor Laboratory, Cold Spring Harbor,  NY) and 
restriction enzyme digestion of  mini-plasmid preparations was used 
to identify the clones containing the gene of  interest. Single-stranded 
DNA was produced using the fl origin of replication present in 
the vector and cloned genes were sequenced by the dideoxy chain 
termination  method (27). 
Transfection and Isolation of Recombinant Viruses.  Transfer  vectors 
ligated to Ig genes were isolated from E. coli BSJ72 as mini prepa- 
rations. This DNA was used to transfect Sf9 cells employing lin- 
earized wild-type viral DNA and cationic liposomes (Invitrogen, 
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fection and screened by plaque assay for occlusion-minus viruses. 
Well isolated plaques were picked and dispersed  into I ml of TNM- 
FH medium. An aliquot of the plaque (200/~1) was used to infect 
2 x  10  s Sf9 cells. At 3-4 d after infection, the cells were pelleted, 
lysed in sample buffer containing/3-ME and run on a 10% SDS- 
polyacrylamide gel. Western blot analysis was performed using 
PVDF membrane  (Immunobilon-P;  Millipore  Corp., Bedford,  MA). 
Both 12SI-labeled goat anti-human IgM and IgG Abs (ICN Flow, 
Costa Mesa, CA) and Chemiluminescence ECL Western blotting 
protocol (Amersham Corp., Arlington Heights, IL) using horse- 
radish peroxidase-conjugated  anti-human IgM or IgG (EY Labora- 
tories Inc., San Mateo, CA) were used to detect the recombinant 
protein products. Viruses were purified  at least twice by plaque assay. 
Recombinant Ab Production.  Recombinant  Abs were synthesized 
in Sf9 cells grown in serum-free medium by coinfecting cells with 
equal amounts of H and L chain producing viruses at an MOI of 
5 for each virus. 3 d after infection, the cell supernatants were con- 
centrated using Centriprep 100 (YM 100 membrane) concentrators 
or stirred ultrafihration  cells  using the YM 100 membrane  (Amicon, 
Beverly, MA). Aliquots of the concentrates were analyzed  by SDS- 
PAGE under nonreducing and reducing conditions and Western 
blotting was used to detect either assembled Abs or separated H 
and L chains, respectively. 
Isolation of  Polyclonal CA from Patient Sera.  Joh (IgM~) and Sch 
(IgMX) CAs were isolated by incubating patient sera with human 
cord blood stroma at 4~  overnight, washing the reacted  cells  with 
cold PBS and eluting the Ig from the stroma with PBS at 37~ 
The eluates were then tested for CA activity by serologic titration. 
These CA are two of the original CA purified and described by 
Williams et al. (1). 
Pre~ration of Absorbed Polyclonal Rabbit Antisera.  Purified  Joh 
and Sch CA eluates from cord blood stroma were mixed with an 
equal volume  of  CFA and injected  subcutaneously  into New Zealand 
white rabbits once a week for 1 mo. The rabbits were bled and 
the antisera absorbed using columns of  immobilized pooled normal 
human IgM (Sigma Immunochemicals, St. Louis, MO) bound to 
Sepharose 4B (Pharmacia, Piscataway, NJ) and subsequently ab- 
sorbed with three different  human monoclonal IgM WaldenstrSm's 
proteins linked to Sepharose  4B, which did not exhibit CA activity. 
The antisera were tested by ELISA  for reactions with their homol- 
ogous CA and other CA eluates. The anti-Joh antiserum reacted 
positively with the Joh eluate but did not react with the Sch CA. 
Conversely, the anti-Sch antiserum reacted with the Sch eluate, 
but did not react with the Job CA. The absorbed antisera, which 
reacted with their homologous eluates, did not react with normal 
IgM nor with isolated IgM paraproteins by ELISA. 
ELISA for 9C4 Reactivities and Testing Absorbed Anti-CA CRI 
Polyclonal Antisera.  The isolation of 9G4 was previously  described 
(3). The mAb SA (IgMX) encoded by the V.4 family member 
V79 was used as immunogen. Reactivity of recombinant Abs with 
mAb 9G4 was measured by ELISA. A sandwich assay was per- 
formed in which 96-well flat-bottomed plates were coated with 
5 #g/ml 9G4 in 0.1 M carbonate buffer, pH 9.2. The plates were 
incubated overnight at 4~  then blocked with PBS containing 
0.05% Tween 20 and 0.25% BSA for 30 min at room temperature. 
The plates were washed three times with water and a twofold dilu- 
tion series of test Abs was added for 2 h at 37~  After washing 
three times with water, bound Ab was detected using alkaline- 
phosphatase-conjugated  goat anti-human IgM Ab (/~ chain specific; 
Sigma Immunochemicals).  This Ab was incubated for 2 h at 37~ 
Unbound Ab was removed  by washing three times and  p-nitrophenyl 
phosphate substrate tablets were dissolved  in 0.1 M diethanolamine 
buffer, pH 9.8, and added to the wells. The absorbance was mea- 
sured at 405 nm in an ELISA  plate reader (Titertek Muhiskan Plus; 
ICN Flow). A capture assay was also used in which wells were 
coated with 5 #g/ml anti-rat IgG Abs, followed by 9G4 and the 
sample Ab which was detected using alkaline-phosphatase-con- 
jugated goat anti-human IgM. The capture assay gave stronger 
reactions than the sandwich assay  within a 30-min reaction time. 
Sandwich assays, essentially as described above, were used to test 
absorbed rabbit  antisera with both homologous  and heterolo- 
gous CA. 
Inhibition ELISA with Rabbit Absorbed Anti-CA CRI Polyclonal 
Antisera. The anti-Id reaction employed for the inhibition experi- 
ments was absorbed anti-Joh  or anti-Sch  reacting  with another cross- 
reactive CA Koe, but not the individually specific  Job or Sch an- 
tigen originally employed to produce the antiserum. The Koe Ab 
was used in order to avoid  background reactions which occur when 
the inducing CA is used. 
The recombinant Abs were diluted to the same protein concen- 
tration and an aliquot was mixed with a 1:500 dilution of absorbed 
anti-CA CKI antisera and incubated for I h at room temperature 
with shaking. The mixture was added to the wells coated with 
Koe at 5 #g/ml and inhibition was detected by comparing the ab- 
sorbance with that of the control lacking recombinant Ab. 
Results 
The  9C4  Idiotope MaFs to  the  VH  Gene  Segment.  The 
structural basis  for  9G4  binding  to  Abs  containing  the 
V.4-21  gene segment was analyzed by expressing the CA 
FS-7H (IgMK), FS-7 H  chain mutants and a number of H 
and L chains in the baculovirus system. The influence of the 
L chain on 9G4 reactivity of the FS-7 H chain was analyzed 
by producing several combinatorial recombinant Abs in which 
the FS-7 Ab L chain was replaced by different L chains of 
both the K and ~, isotypes. This was accomplished by coin- 
fecting monolayers of Sf9 cells with the same FS-7 H chain 
virus and different L chain viruses. As shown in Table 1, all 
of the Abs containing the FS-7 H  chain, irrespective  of its 
paired L chain, were reactive with 9G4. The Ab composed 
of the K chain from the mouse anti-arsonate Ab 91A3 (28) 
combined with the FS-7 H chain also reacted with 9G4. The 
Ab containing the FS-7 K chain paired with the Ab25 (an- 
tithyroglobulin)/~ chain, which uses  a VH3 gene segment 
(24), did not bind 9G4. Exchange of the V.3 gene segment 
utilizing RF-TS2 (IgMK; 29) H chain, for the FS-7 H chain, 
converts a nonreactive Ab to a reactive one. The FS-7 H chain 
alone did not bind 9G4. This may indicate that there is some 
involvement of the L chain in stabilizing the conformation 
of the epitope in the H chain. The X isotype containing Igs, 
anti-hepatitis B virus surface antigen antibody L chain c~HBVX 
OST 577 (30) paired with FS-7/~, FS-3X (8) paired with FS- 
7/~ and FS-3X paired with FS-6/~ (8),  all bound 9G4 com- 
parably with the K-containing antibodies. This further sub- 
stantiates the conclusion that the idiotope to which 9G4 binds 
is localized solely to the H  chain. 
Abs containing the H chain of CA FS-6 were also reactive 
with 9G4. The FS-6 antibody utilizes the V,4-21 gene seg- 
ment and has I antigen specificity (8).  In FS-6, the V.4-21 
segment contains four amino acid mutations with respect to 
the germline sequence; one in each of FR1, CDR1, CDR2, 
1421  Potter  et al. Table  1.  Reactivity of CA FS-7 and Combinatorial Abs with 9G4 
L  chain  VL family  H  chain  V.  family  9G4 reactivity 
FS-7x  xl  FS-7#  4  +  +  + 
RF-TS2r  r3a  FS-7#  4  +  +  + 
RF-TMClr  x3  FS-7g  4  +  +  + 
37-2r  r3b  FS-7g  4  +  +  + 
91A3r  rl0  FS-7g  4  +  +  + 
HBV~, OST  577  )~5  FS-7g  4  +  +  + 
FS-3~,  hl  FS-7/z  4  +  +  + 
FS-3)~  hl  FS-6/z  4  +  +  + 
FS-7K  rl  FS-6g  4  +  +  + 
FS-7r  rl  FR1(4-21)  4  +  +  + 
FS-3X  ~,1  FR1(4-21)  4  +  +  + 
RF-TS2x  r3a  FKl(4-21)  4  +  +  + 
FS-7r  rl  V71-2  4  - 
FS-3X  )~1  V71-2  4  - 
FS-7x  rl  Ab25#  3  - 
37-2r  r3b  Ab25#  3  - 
RF-TS2x  r3a  RF-TS2/z  3  - 
HBV~, OST  577  )~5  HBV'y OST  577  3  - 
-  -  FS-7g  4  - 
Combinatorial Abs were produced by coinfecting SF9 cells with the H and L chain producing indicated viruses. Purified Abs were tested for reactivity 
with 9G4 by ELISA. RF-TS2K is a RF L chain  (11),  37-2x is an antiacetylcholine  receptor  L chain  (54),  HBV)~ OST 577 (30) is an antihepatitis 
B virus surface antigen  Ab, and 91A3 is a mouse anti-arsonate Ab L chain (28). Ab25g is an anti-thyroglobulin Ab H  chain (24), and FR1 (4-21) 
is the parental  V71-2 recombinant  antibody with the FR1 sequence replaced by the FR1 sequence of V,4-21. ( + + + ) OD40s 0.8-1.0;  ( -  ) OD40s 
<0.2. 
VH6"21 
V71-2 
CDR1 
a  v  Q  L  o  Ja  u  ~  A  ~  L  L  JK  P  S  E  T  L  S  L  T  C  JA  V  *  a  ~  S  F  S  G  Y  Y  w  s  u  I  R  Q  P 
￿9 **  ***  TACTACTG~GCTGGATCCGCCAGCCC  CAGGTGCAGCTACAGICAGTGGGGCCGAGGACTGTTGIAAGCCTTCGGAGACCCTGTCCCTCACCTGCI  GCTGTCTATGGTGGGTCCTTC  AGTGGT 
...........  G---IG---C .....  C  .......  G--I .............................  "JA ......  C  ......  C---G--AGC ......  AGT  ....................  G  ..... 
J  1  [ 
VH4-21 
V71 - 2 
CDR2 
*********************************************** 
e  G  K  G  L  E  W  ]  G  IE  I  N  H  IS  G  S  T  N  Y  N  P  S  L  K  S  R  V  T  |  $  V  D  T  S  K  N  Q  F  S  t  K  L  S 
CCAGGGAAGGGGCTGGAGTGGATTGGG  GAAATCAATCAT[  AGTGGAAGCACCAAC•ACAACCCGTCCCT•AAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAAC•AGTTCTCCCTGAAGCTGAGC 
...........  A ...............  T-T---T--T-C[ .....  G  .................  C .................................................................. 
Y  Y  Y  I 
J 
S  V  T  A  A  D  T  A  V  Y  Y  C  A  R 
VH4-21  TCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGA 
V71-2  ...........  T ...........  C .................. 
Figure  1.  Comparison of the amino acid sequences of V.4-21  and V71-2 gene segments. (Dashes) Identical  amino acids. (Stars within box)  Cor- 
respond to extra bp in the V71-2 sequence. Boxed areas enclose regions of sequence differences between the two gene segments and indicate the V.4--21 
amino acids that were exchanged  for V71-2 amino acids. 
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Figure  2.  Generation  of FS-7 mutants  by interchange  with V71-2 
sequences. (Solid black areas) V.4-21 sequences; (hatched areas) V71-2 se- 
quences. The V.4-21 amino acids were exchanged for those of V71-2 and 
vice-versa by PCR-SOEing mutagenesis.  All H  chains were paired with 
the FS-TK chain.  (25Y-,'25F)  Exchange of tyrosine for phenylalanine  at 
position 25. (+ + +) OD40s 1/41.2-1.6; (+ +) OD4os 0.8-1.2; (+) OD40s 
0.4-0.8;  (-) OD40s <0.4. 
and FK3 (8).  None of these mutations affects the binding 
of 9G4, which is in agreement with previous results (8). Since 
there is no sequence homology  between the CDP,3s of FS-7, 
which has 14 amino acids compared with 13 amino acids in 
FS-6,  it is concluded that this portion of the Ab molecule 
is not responsible for the CKI. 
The # chains FS-7, FS-6, RF-TS2, and Ab25 have the same 
C region sequences, all being PCR amplified from the Ab25 
clone, indicating that the idiotope is not influenced by the 
C region. These data definitively localize the 9G4 idiotope 
to the V.4-21 gene segment. 
The 9G4 Idiotope Maps to FR1.  The approach used to fur- 
ther delineate the amino acids comprising the 9G4 idiotope 
involved exchanging V.4-21 sequences with those from the 
V71-2 gene segment. V71-2 is a member of the V.4 family 
which is not associated  with Abs having CA activity nor 
with Abs  having 9G4  reactivity (4).  Comparison of the 
V,4-21 and V71-2 amino add sequences revealed three areas 
of sequence distinction as shown in Fig. 1. The first area in- 
volves  the  NH2-terminal portion of FP,1  which contains 
four amino acid differences. The second area encompasses the 
COOH-terminal portion of FR1 and part of the flanking 
CDB.1. This involves three amino acid differences along with 
a V71-2 CDR1 which contains two more amino acids than 
the  V.4-21  CDR1.  The  third  area  involves  the  CDR2 
where the sequences differ by three amino adds. Mutant Abs 
were constructed and named N-FW1, C-FW1/CDR1, and 
CDR2 reflecting the three areas differing between the two 
V. gene segments. As shown in Fig. 2, both N-FW1 and 
CDR2 reacted positively with 9G4 in the ELISA, although 
the N-FW1  reaction was weak. The C-FW1/CDR1 mu- 
tant was nonreactive. These results indicate that the 9G4 CRI 
is predominantly localized to the C-FR1/CDP,1  area. 
The  9G4  Idiotope Maps  to  FRI  Amino  Acid  Position 
23-25.  As shown in Fig. 2, the ELISA results indicated that 
both V.4-21  mutants which either had the entire FR1 ex- 
changed for the V71-2 sequence (mutant FR1 [71-2]) or only 
Table  2.  Inhibition of Anti-Job Polyclonal Rabbit Antiserum Reacting with Koe CRI + CA  by Recombinant Abs 
Ab 
L chain  #H chain  JOH anti-Id reactivity  SCH anti-Id reactivity 
FS-7x  FS-7  +  +  +  - 
FS-3),  FS-7  + + +  - 
FS-7K  CDIL1  + + +  - 
FS-7x  CDR.2  + +  - 
FS-7x  FR1  (4-21)  + + +  ND 
FS-3)~  FR1 (4-21)  + + +  ND 
P,F-TS2K  FR.1 (4-21)  -  ND 
FS-TK  FP,1 (71-2)  -  - 
FS-7x  71-2  -  ND 
FS-3)~  71-2  -  ND 
FS-7K  C-FW1  + +  - 
FS-7x  C-FW1/CDIL1  -  - 
Koe CA positive control  + + +  - 
Wild-type virus  -  - 
Recombinant Abs were adjusted to equal protein concentrations  and an aliquot mixed with a 1:500 dilution of absorbed anti-Joh or anti-Sch antisera 
and incubated  at room temperature with shaking for 1 h. The mixture was added to wells coated with 5/~g/ml CA Koe and the absorbance measured 
relative to the anti-Joh/Koe interaction to determine inhibition. 
( + + + ) Inhibition at >0.2 ~g/ml inhibitor; ( +  + ) inhibition at 0.8-0.2/~g/ml inhibitor; ( -  ) no inhibition at 3.5/~g/ml inhibitor. ND, not done. 
1423  Potter et al. the portion of FR1 adjacent to the CDR1 exchanged for the 
V71-2 sequence (mutant C-FW1), were not reactive with 
9G4. The nonreactive parental V71-2 antibody was converted 
to 9G4 reactivity when the FR1 of V71-2 was replaced with 
the V,4-21  FR1  sequence in mutant FR1(4-21). The mu- 
tant CDR1, which was composed of a V~4-21 sequence but 
exchanged in the CDR1 for a V71-2 CDR1 sequence, was 
9G4 reactive. CDR1, therefore, is not involved in forming 
the 9G4 reactive idiotope. This result also indicates that the 
length of the CDR1, which is longer in V71-2 by two amino 
adds, is not a factor in 9G4 binding. This pattern of reac- 
tivity identifies the idiotypic site as comprising amino acids 
23-25 of FR1 having  the amino acid sequence AVY. 
An inspection of published amino acid sequences indicates 
that the hydroxyl containing amino acids serine and tyrosine 
are usually found at position 25 in FR1 in both 9G4 reactive 
and nonreactive Ig (5-11, 13, 24, 30-32).  The influence of 
a hydrophobic amino acid lacking a hydroxyl group at posi- 
tion 25 was investigated by replacing the tyrosine residue in 
FS-7 with phenylalanine. The Ab labeled 25Y---~25F was pro- 
duced and tested for 9G4 reactivity (Fig. 2).  The Ab was 
9G4 reactive indicating that the absence of a hydroxyl group 
and the change from a polar to a nonpolar residue in this 
position did not significantly effect the structure of the CRI. 
The Reactivity of Absorbed Anti-CA CRI Polyclonal Rabbit 
Antiserum Maps to FRI.  The recombinant FS-7 CA and mu- 
tants were incubated with absorbed anti-CA CRI polyclonal 
rabbit anti-Job and anti-Sch antisera in an inhibition ELISA. 
As shown in Table 2, the parental 71-2 Abs, mutants FR1(71- 
2), C-FW1/CDR1 and FR1(4-21) paired with RF-TS2K did 
not inhibit the anti-Joh/Koe reaction.  The parental FS-7, 
CDR1 and FR1(4-21) paired with either FS-7K or FS-3X were 
the best inhibitors, with inhibition detected at 0.2-0.4/~g/ml 
of Ab. The remaining mutants CDR2 and C-FW1 demon- 
strated intermediate activity. This pattern of inhibition using 
the anti-Joh antiserum, with the exception of the C-FW1/ 
CDR1 and RF-TS2 K/FR1 (4-21) results, indicates that this 
polyclonal antiidiotypic  antiserum is also detecting a deter- 
minant in FR1,  predominantly at  the NH2-terminal  end. 
The anti-Joh antiserum also was inhibited by the combina- 
torial Ab FS-3~,/FS-7/~. No inhibition was detected using 
the anti-Sch antiserum against any of the recombinant Abs 
employed in these studies. Reactivity assays of the Job and 
Sch eluates with 9G4 indicate that these CA are both 9G4 
reactive. It is most likely, therefore, that both of these Abs 
are derived from the V,4-21  gene segment. 
Discussion 
In this  study we investigated the primary structure and 
location of the 9G4 cross-reactive Id on the VH4-21 gene 
segment using site-directed mutagenesis. Amino acids from 
the V71-2 gene segment (Id negative), which differ between 
the V.4-21 and V71-2 gene segments, were substituted for 
the V,4-21 sequence of FS-7, a CA which expresses a germ- 
line  copy  of the V.4-21  gene segment (8).  Our  results 
clearly indicate that the FR1 region of CA Abs utilizing the 
VH4-21 gene segment is responsible for binding to the anti- 
Id Ab 9G4, and more specifically, the amino acids AVY in 
FR1 have been found to be the reactive site. Replacement 
of the FR1  sequence of V71-2 with the V,4-21  FR1  se- 
quence in mutant FR1(4-21) converted the Id negative V71-2 
antibody to Id positive. In mutant C-FW1/CDR1, the sub- 
stitution of VH4-21 amino acids AVY for V71-2 amino acids 
TVS at position 23-25, renders the Ab nonreactive with 9G4. 
When the V.4-21 sequence AVY is added back to the FR1 
(mutant CDR1),  the reactivity with 9G4 is restored. 
A comparison  of published  FR1  sequences from Abs of 
known sequence,  which are either reactive or nonreactive with 
9G4, is shown in Table 3. All Igs reactive with 9G4 share 
the AVY motif in FR1, however, when the alanine at posi- 
tion 23 is replaced by threonine as in Ab26,  C6B2,  PAG1 
and 2A4 or lysine as in RF-BOR, RF-TS1, RF-TS3, 9G4 re- 
activity is abolished. The valine at position 24 is also impor- 
tant since  its replacement  by alanine  in a number of Abs renders 
them nonreactive with 9G4.  In addition to the sequences 
shown in Table 3, 14 IgM clones from B cell tumors, 10 IgG 
clones from normals and 21 IgM clones from patients with 
infectious mononucleosis  were all 9G4 reactive, and all 45 
clones utilized the V.4-21  gene segment having  the FR1 
AVY motif (33). 
This molecular localization of this idiotope also explains 
the negative 9G4 response of FOG 1, an anti-RBC D  an- 
tigen Ab which uses the V,4-21 gene segment (12). FR1 
of FOG 1 differs from the germline sequence at position 25 
and contains a histidine, a basic amino acid that renders the 
Ab 9G4 negative. Since many of the CA use the V.4-21 
gene segment mutated from the germline sequence (8), it 
is possible that a spontaneous mutation would occasionally 
occur in the FR1 segment recognized by 9G4. A mutation 
in this area does not appear to be a frequent event as a number 
of CA have been sequenced and other mutations have not 
been detected at this position (Table 3). Some mutations, how- 
ever, are tolerated as the mutant 25Y-~25F, in which the tyro- 
sine at position 25 was replaced by phenylalanine, was still 
reactive with 9G4. Therefore, there is no absolute require- 
ment for a hydroxyl containing amino acid at position 25 
of FR1. The presence of a basic amino acid such as histidine 
at position 25, however, appears to be su~cient to abrogate 
9G4 binding. Our conclusion that the 9G4 Id maps to FR1 
is in agreement with the prediction  of Silberstein et al. (5) 
that the 9G4 idiotope  could be associated with conserved 
residues in the FR1 portion adjacent to the first CDR. The 
lack of reactivity of the H chain alone suggests that the de- 
terminant requires a specific conformation which is perhaps 
stabilized by the L chain. 
The CA CRI was the first demonstration of shared Id 
among Abs from unrelated individuals (1). Since that time, 
other CRI have been described. Kunkel et al. (34) demon- 
strated that RF from unrelated individuals shared CRI. Two 
of these CRI have been localized to the CDR2 and CDR3 
of the K chain (35). The anti-DNA Ab-associated Id 8.12 
is present in X chains in the vicinity of the CDR1 (36). The 
CDR2 and/or CDR3 provide the Id determinations in Abs 
to p-azophenylarsonate (37), phosphorylcholine (38), c~(1-3) 
ce(1-6) dextrans (39, 40), and 3(1-6) galactan (41). Different 
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Clone  FR1  sequences  VH family  GL  donor  Specificity  Id 9G4  Reference 
FS-7 
FS-1 
FS-2 
FS-3 
FS-4 
FS-5 
FS-6 
FS-8 
Abl7 
CAP(15A) 
VOG(20A) 
LES 
PR-TS2 
KAU 
A483 
N6 
N26 
Nl15 
N127 
N184 
N187 
O15 
026 
P5 
HY18 
FOM  1 
FOM A 
MAD  2 
T14 
FOG  1 
Ab26 
C6B2 
PAG  1 
FOG  B 
HAM B 
FOG  3 
BOR 
RF-TS1 
R.F-TS2 
RF-TS3 
RF-SJ2 
RF-AN 
L16 
2A4 
HBVOST577 
Ab25 
QVQLQQWGAGLLKPSETLSLTC  AVY GGS 
............................ 
-  -H  ....  T  .............. 
...................... 
...................  p_  - 
....  H  .................... 
......................... 
...........  V ........  A .... 
......................... 
....................  N  .... 
-  -H  .................  N  .... 
......................... 
......................... 
......................... 
......................... 
......................... 
......................... 
......................... 
......................... 
......................... 
......................... 
.......................... 
......................... 
......................... 
......................... 
......................... 
.....  ES  .................. 
-  -H  .....  T  ............. 
.....  ES-P-  -V-  -  -Q ...... 
.....  ES-P--V---Q  ...... 
.....  ES-P--V  .......  V-- 
-LR--ES-P--V  .......... 
..... XS-G-VVQ-GRS-R-S- 
..----S-G-VVQ-GRS-R-S- 
E---V-S--EVK--GSSVKVS- 
L---V-S--EVK--GSSVKVS- 
.... VES-G-VVQ-GRS-R-S- 
.... V-S-SELK--GASVKVS- 
.... V-S-G-VVQ-GRS-R-S- 
E .... ES-G-LVQ-GRS-R-S- 
......  s-P--V---Q  ...... 
.....  ES-P--V---Q  ...... 
....  VES-G-VVQ-GRS-R-S- 
E---LES-G--VQ-GGS-R--- 
--H 
T-S 
T-S 
T-S 
S-S 
-AS 
-AS 
KAS 
KAS 
-AS 
KAS 
-AS 
VTS 
-IS 
T-S 
-AS 
-AS 
4  4-21  CA(I)  +  8 
4  4-21  CA(I)  +  8 
4  4-21  CA(I)  +  8 
4  4-21  CA(i)  +  8 
4  4-21  CA(I)  +  8 
4  4-21  CA(i)  +  8 
-  -  -  4  4-21  CA(1)  +  8 
-  -  -  4  4-21  ND  +  8 
-  -  -  4  4-21  PR  +  24 
-  -  -  4  4-21  CA(i)  +  5 
-  -  -  4  4-21  CA(I)  +  5 
-  -  -  4  4-21  RF  +  5 
-  -  -  4  4-21  PR  +  11 
-  -  -  4  4-21  CA(I)  +  7 
-  -  -  4  4-21  -  +  13 
-  -  -  4  4-21  -  +  13 
-  -  -  4  4-21  -  +  13 
-  -  -  4  4-21  -  +  13 
-  -  -  4  4-21  -  +  13 
-  -  -  4  4-21  -  +  13 
-  -  -  4  4-21  -  +  13 
-  -  -  4  4-21  -  +  13 
-  -  -  4  4-21  -  +  13 
-  -  -  4  4-21  -  +  13 
-  -  -  4  4-21  CA(i)  +  6 
-  -  -  4  4-21  D  +  9 
-  -  -  4  4-21  D  +  9 
-  -  -  4  4-21  D  +  9 
-  -  -  4  4-21  DNA  +  10 
-  -  -  4  4-21  D  -  *  9 
-  -  -  4  71-4  PR  -  24 
-  -  -  4  71-4  PR  -  5 
-  -  -  4  71-4  D  -  9 
---  4  2-1  D  -  9 
- FT  3  DP50  D  -  9 
- FT  3  DP50  D  -  9 
-  DT  1  -  RF  -  31 
-  DT  1  HON-1  RF  -  11 
-  FT  3  19.III  RF  -  11 
-YT  1  4.16  RF  -  11 
- FT  3  56P1  RF  -  11 
-  FT  3  26  RF  -  11 
-  D-  6  PR  -  5 
-  -  -  4  71-2  DNA  -  32 
- FT  3  1.9111  HBVsAg  -  30 
- FT  3  J00236  TG  -  24 
CA(I), cold agglutinin anti-I; CA(i), cold agglutinin anti-i; PR, polyreactive; D, red blood cell D antigen; HBVsAg, hepatitis B virus surface antigen; 
TG,  thyroglobulin. 
" The only VH4-21-derived Ig that is 9G4  negative. CD4-specific mAbs were found by site-directed mutagenesis 
to have Ids located in the CDR2 and CDR3 (42), however, 
loss of the Id determinants did not signifcantly affect an- 
tigen binding. The Id in anti-o~(1-6) dextran is associated 
with the V. CDR2 (43),  and again, loss of the Id did not 
affect antigen binding. 
The above examples indicate that the majority of identified 
CR.I are located in the CDRs and hence, have the potential 
of being closely related to the antigen-combining site. Not 
all anti-Id determinants on the V region of an Ab, however, 
are formed by the CDRs as there are a few examples where 
specific Ids map to  framework regions.  Anti-DNA  CRI 
(thought to be the 31 Id) were directed against framework 
determinants (44) and a polyclonal rabbit antiserum recog- 
nized a number of mouse mAbs whose determinants were 
localized  to FR1 and FR3 residues  (45).  The role of FR 
sequences in determining Ab specificity by influencing the 
three-dimensional conformation of the H chain is still poorly 
understood. FR1 is a solvent-exposed segment and is struc- 
turally separated from the antigen binding site (46). Residues 
in the FR near the CDR boundaries, however, often directly 
contribute to the correct folding of the Ab binding region 
(47-49). The location of the 9G4 reactive determinant in FR1 
implies that this marker is not associated with the antigen- 
combining site and hence, is consistent with the findings that 
this site is detected on Abs with unrelated binding specifcities. 
The I/i carbohydrate antigens on the surface of RBCs are 
the most frequent specificities of CA. These antigens are com- 
posed of repetitive N-acetyllactosamine units which are linear 
in the i structure and branched in the I structure by virtue 
of a Gal-GlcNAc attached in B1-~6 glycosidic linkage to galac- 
tose residues (50). A study by Feizi et al. (51), using 11 mono- 
clonal anti-I Abs, determined that there are three types of 
blood group I specificities suggesting the presence of three 
major structural domains within the I molecule. None of 
the 11 mAbs, however, recognized the same antigenic deter- 
minant on the I structure, indicating that these Abs possess 
a wider range of fine specificities. This finding is consistent 
with the sequence data which demonstrated that Abs with 
CA activity, and having highly homologous V. regions, all 
had different CDR3 sequences. This suggests that CA are 
interacting with I/i antigens through the conventional Ab 
combining site formed by the association  of the H  and L 
chains. Because of the structural unrelatedness of the autoan- 
tigens recognized by V.4-21-derived  Abs,  it  is  possible, 
therefore,  that the fine specificity of V.4-21-derived Abs is 
determined by the CDR3, with involvement of the L chain, 
whereas the gross I/i specificity is regulated by the V~4-21 
region, as also suggested by Silberstein et al.  (5). 
The structural relationship between the site recognized by 
9G4 and the antigen binding site is still unclear. It was demon- 
strated that after interaction between CA and 9G4, CA are 
unable to agglutinate RBCs (12, 52). This has been inter- 
preted to mean that the I/i binding site and the 9G4 binding 
site are in close proximity. Alternate explanations could be 
that the structure of a more distally located antigen-combining 
site is altered after 9G4 binding, which results in the impair- 
ment of these Abs to agglutinate RBCs or that steric hin- 
drance after 9G4 binding prevents agglutination. The local- 
ization of the 9G4 determinant to the FR1 indicates that one 
of the latter hypotheses is likely correct. I/i binding analysis 
using our recombinant FS-7 mutants, which no longer con- 
tain the 9G4 idiotope will provide additional information re- 
garding the relationship between the 9G4 idiotope and I/i 
binding regions. 
The absorbed polyclonal rabbit anti-Joh antiserum also de- 
tected a determinant located in FR1. TheJoh CA is an IgMg 
Ab with anti-I activity (53), whereas the Sch CA is IgMS 
with both anti-I and anti-i activity (1, 17). Although both 
of these Abs were found to react positively with 9G4, they 
only reacted with their homologous absorbed rabbit anti-Id 
antiserum. This implies that the antisera are detecting deter- 
minants provided by both the H and L chains and possibly 
explains the lack of reactivity of mutant FR1 (4-21) paired 
with RF-TS2K. It is unclear why the C-FW1/CDR1 mutant 
did not inhibit the anti-Joh/Koe reaction, whereas the C-FW1 
and CDR1 mutants did. This may be a reflection of the com- 
position of the polyclonal antiserum which has the ability 
to recognize multiple epitopes combined with a potential al- 
teration in the three-dimensional structure of the Ab which 
resulted from simultaneously mutating both the FR1 and 
CDR1 areas. 
Since both the 9G4 determinant and a CRI recognized 
by specifically absorbed antiserum are localized to FR1, these 
data underscore the influence this solvent-exposed region of 
the Ab plays with respect to the antigenicity of Igs. The main- 
tenance  of the  AVY  sequence  in  Abs  derived from  the 
V.4-21 gene segment suggests that it has an important role 
in determining the biological activity of these Abs. The 9G4 
Id is a marker for a germline gene segment that is found in 
10% of all B cells in the normal human population (52). As 
a number of 9G4 reactive Abs are autoreactive,  mechanisms 
that control the overproduction of these Abs must be opera- 
tive under normal conditions. Some of these mechanisms may 
involve an idiotypic network based on determinants located 
in FR1 to control the quantity of Ig produced. Breakdown 
of the regulated synthesis of these Ig appears to lead to the 
overproduction of Abs with autoreactivity. Analysis of the 
9G4 idiotope extends out understanding of the physical prop- 
erties of a very interesting group of Abs and a genetic com- 
ponent involved in autoreactivity.  Further expression studies 
are required to establish the relative positions of the 9G4 Id 
and the antigen-combining site. This information will poten- 
tially explain the restricted use of the VH4-21 gene segment 
in CAs with anti-I/i specifidty, the role of the H chain CDR3, 
and the contribution of L  chain in determining antigen 
specificity. 
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